SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guidant (GDT)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Donald carlson who wrote (200)7/22/2002 9:58:16 AM
From: Lighthouse   of 235
 
Everolimus is the only announced internal program with GDT. They have stated that there are other compounds under review. The problem is Everolimus is still in animal testing and will not be on the market before very late 04, but more likely 05. That is if the results carry over to humans. A big "IF". The other compounds under review have an even longer time line. Having no products for their stent sales force to sell is suicide. Dollens, on the conference call, stated that by the end of the year we will have much, much more visabiliy on how GDT is tackling this issue. My bet is we know a lot more by the end of August.

I am leaning toward them buying Cook. Paxlitaxel looks like it is comparable to JNJ's program.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News